Gland Pharma Shares Soar 8% on Robust Q3 Results, GLP Opportunity
Market
C
CNBC TV18•29-01-2026, 09:28
Gland Pharma Shares Soar 8% on Robust Q3 Results, GLP Opportunity
- •Gland Pharma shares surged 8% after reporting strong December quarter results, with revenue up 22.5% year-on-year to ₹1,695.3 crore.
- •EBITDA grew 21% and profits increased 27%, while margins remained stable at 25.7%.
- •Growth was broad-based across geographies: US business up 19%, India up 32%, and European business up 54%.
- •New contracts in the US market and improved Cenexi margins contributed to the positive performance.
- •The company anticipates the emerging GLP drug opportunity to be a significant growth driver for the upcoming financial year.
Why It Matters: Gland Pharma's strong Q3 performance and future GLP drug prospects fueled an 8% share price jump.
✦
More like this
Loading more articles...
